# Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

> **NCT02273050** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1136 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Saxagliptin 5 mg
- **DRUG:** Placebo 5 mg for Saxagliptin
- **DRUG:** Placebo 500 mg for metformin (with titration)
- **DRUG:** Metformin 500 mg with titration

## Key facts

- **NCT ID:** NCT02273050
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 1136 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273050, "Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02273050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*